Group 1 - On March 3, 2026, Fonda Holdings, a subsidiary of Tiger Med Group, announced the completion of its acquisition of Guanhua Medical, enhancing Fonda's global central laboratory capabilities and service capacity in China and the Asia-Pacific region [1] - Guanhua Medical is a leading clinical research laboratory service provider in China, having supported over 1,500 clinical trials across multiple therapeutic areas, and has extensive experience in regulatory compliance and high-quality laboratory testing services [1] - Following the acquisition, Fonda Holdings aims to expand its central laboratory network in China and improve its comprehensive support for domestic clinical research and multi-regional clinical trials (MRCT) [1] Group 2 - A representative from Fonda Holdings stated that the integration of Guanhua Medical is a significant step in Fonda's global development, aligning with Fonda's commitment to quality and compliance standards [2] - The acquisition is part of Fonda Holdings' ongoing efforts to enhance its global footprint, leveraging a unified quality system and operational standards to improve collaboration between China and the U.S. and accelerate the delivery of innovative drugs to international markets [2] Group 3 - Fonda Holdings is a comprehensive pharmaceutical R&D CRO with established centers in China, North America, and Europe, providing a wide range of services including drug chemistry, pharmacology, DMPK, and clinical research [3] - The company adheres to a "global unified quality system" and has successfully passed over 350 audits from regulatory agencies, including more than 200 from the FDA, over its 25 years of operation [3]

Core Insights - Fonda Holdings and GCCL signed a strategic memorandum of understanding (MOU) to enhance their influence in the global clinical trial market [1][3] - The collaboration aims to leverage both companies' service and laboratory network advantages to improve competitiveness in the US and Asia-Pacific regions [1][3] Company Overview - GCCL is a leading clinical trial sample analysis provider in South Korea, offering integrated "one-stop solutions" including central laboratories and bioanalytical laboratories [4] - Fonda Holdings is a comprehensive pharmaceutical R&D CRO with established centers in China, North America, and Europe, providing a wide range of outsourced R&D services [5] Strategic Collaboration - The partnership will explore joint clinical trial services, co-marketing, project support plans, and the development of new business opportunities [3] - Both companies will combine their regional expertise and global networks to execute clinical trial projects more efficiently and effectively [3] Leadership Statements - Fonda Holdings' Senior Vice President, Dr. Zhang Nan, emphasized the importance of this strategic cooperation in enhancing their influence in the Asia-Pacific market and providing faster, more efficient support for global clinical trials [3] - GCCL's CEO, KwanGoo Cho, highlighted the goal of creating new growth opportunities in the global clinical trial market by combining GCCL's strengths in bioanalysis and central laboratory services with Fonda's global capabilities [3]